Riskpilot← Back to searchSign inGet full accessNiklmark Medical AB
ABActiveOrg 5590868260Tremarksgatan 5General medical practice activities · NACE 8621Est. 20160 employees
Revenue 2025
SEK 85K
-33% vs 2024
EBITDA margin
-8.0%
-119% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
SEK -7K
-125% vs 2024
| Revenue | SEK 85K | -33% |
| EBITDA | SEK -7K | -119% |
| Net profit | SEK -7K | -125% |
| Total assets | SEK 147K | -12% |
| Equity | SEK 147K | -4% |
| Employees | 0 | — |
Legal name
Niklmark Medical AB
Org number
5590868260
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
24 november 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva annan allmän öppen hälso- och sjukvård så som konsultuppdrag inom det medicinska området, medicinska sakkunniguppdrag, produktion av läromedel, läroböcker och undervisningsmaterial, tillverkning av laboratoriematerial och utrustning samt därmed förenlig verksamhet.
Address
Tremarksgatan 5
Email
niklmarkmedical@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 56 | 115 | 133 | 127 | 85 |
| Staff expenses | — | −0 | −10 | −36 | −26 |
| EBITDA | 17 | 38 | 7 | 35 | −7 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 17 | 38 | 7 | 35 | −7 |
| Net financials | — | 0 | 0 | 1 | 0 |
| Profit before tax | 18 | 38 | 8 | 36 | −7 |
| Tax | −4 | −7 | −2 | −9 | — |
| Net profit | 14 | 31 | 6 | 26 | −7 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 98 | 126 | 135 | 168 | 147 |
| Equity | 90 | 121 | 127 | 154 | 147 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 8 | 5 | 8 | 14 | 0 |
| Total debt | 8 | 5 | 8 | 14 | — |
EBITDA margin
-8.0%
This company
15.8%
Market median
-151% vs market
20212025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20212025
Return on equity
-4.4%
This company
18.4%
Market median
-124% vs market
20212025
Net profit margin
-7.7%
This company
8.1%
Market median
-195% vs market
20212025
Asset turnover
0.58×
This company
1.12×
Market median
-48% vs market
20212025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PN Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Niklmark Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Niklas Marklund | Chief Executive Officer | 0 companies |
| Oscar Bengt Hugo Marklund | Board of Directors | 0 companies |
| Elin Charlotta Nike Stenhammar | Board of Directors | 0 companies |
| Pia Charlotta C Zingmark Marklund | Chairman | 0 companies |